Mortality and progression to AIDS after starting highly active antiretroviral therapy

AIDS

Volumn 17, Issue 15, 2003, Pages 2227-2236

  Van Sighem, Ard I ^a   Van De Wiel, Mark A ^b   Ghani, Azra C ^c   Jambroes, Mariëlle ^d   Reiss, Peter ^a   Gyssens, Inge C ^e   Brinkman, Kees ^f   Lange, Joep M A ^a   De Wolf, Frank ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d Netherlands Association for Community Health Services   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

AIDS; Antiretroviral therapy; HIV; HIV related mortality; Mathematical models; Prognosis; Survival

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0242301662     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200310170-00011     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
3. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
4. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P and the Advanced HIV Disease Ritonavir Study Group. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS 1998; 12:1495-1502.
5. Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. AIDS 1999; 13:851-858.
6. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. CID 2001; 32:1487-1493.
7. Lewden C, Raffi F, Chêne G, Sobel A, Leport C, and The APROCO Study Group. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy. J Acquir Immune Defic Syndr 2001; 26:480-482.
8. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
10. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13:1099-1107.
11. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-395.
12. Nieuwkerk PT, Sprangers MAG, Burger DM, Hoetelmans RMW, Hugen PWH, Danner SA, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 Infection in an observational cohort study. Arch Intern Med 2001; 161: 1962-1968.
13. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA 1996; 276:1955-1956.
14. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
15. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002, updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-235.
16. Ruiz L, Carcelain C, Martínez-Picado J, Frost S, Marfil S, Paredes R, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F19-F27.
17. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F29-F40.
18. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Nat Acad Sci 2001; 98:15161-15166.
19. Taffé P, Rickenbach M, Hirschel B, Opravil M, Furrer H, Janin P, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS 2002; 16:747-755.
20. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126: 946-954.
21. De Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11: 1799-1806.
22. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999; 282. 2220-2226.
23. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-2257.
24. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-868.
25. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999; 130:570-577.
26. De Wolf F, Lange JMA, Bossuyt PMM, Dijkgraaf MGW, Burger DM, Nieuwkerk PT, et al. The ATHENA cohort study: implications of the introduction of HAART for the course of HIV-1 disease, public health and health care as well as the economic costs and benefits. In: Monitoring of Human Immunodeficiency Virus Type 1 (HIV-1) Infection in The Netherlands. July 2001. Amsterdam: HIV Monitoring Foundation; 2001. pp. 18-51.
27. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
28. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41:1-19.
29. Statistics Netherlands. Available at: http://www.cbs.nl.
30. Van Houwelingen HC, Eilers PHC. Non-proportional hazards in models in survival analyis. In: Bethlehem JG, Van der Heijden PGM (editors): COMPSTAT, Proceedings in Computational Statistics. Physica-Verlag; 2000, pp. 151-160.
31. Rancinan C, Neau D, Savès M, Lawson-Ayayi S, Bonnet F, Marcié P, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16:1357-1362.
32. D'Arminio Monforte A, Cozzi Lepri A, Rezza C, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14:499-507.
33. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results form a single treatment centre. AIDS 2001; 15:185-194.
34. 6/l. AIDS2002; 16:1371-1381. 2236